News From Our Partners

Six-year Efficacy Data for GARDASIL® 9 Presented at EUROGIN 2017 Congress

Posted 10/11/17

KENILWORTH, N.J.—(BUSINESS WIRE)— Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced results from final analyses of the pivotal Phase III efficacy, immunogenicity, and safety clinical trial for GARDASIL® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). The data, which showed sustained efficacy for up to six years in the per protocol population, were presented during an oral session at the European Research Organization on Genital Infection and Neoplasia(EUROGIN) congress in Amsterdam, Netherlands.

Please click here for the full report.

Connect with us on: